ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

HIND vs BOLT // EV/EBITDA & P/E VALUATION

Vyome Holdings Inc. (NASDAQ) VS. Bolt Biotherapeutics Inc. (NASDAQ) • 15-METRIC TALLY: HIND 2 — BOLT 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HIND VS. BOLT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC HIND BOLT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 68.40% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) -65.00% 0.10% -65.10 BOLT /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 HIND /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 40.9 75.2 -34.32 BOLT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $12.3M $12.3M $30.9K HIND /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR HIND REV BOLT REV HIND GROSS % BOLT GROSS % HIND FCF BOLT FCF
FY 2025 $319.7K $7.7M 68.4% — -$3.7M -$39.9M
FY 2024 $8.0M $7.7M 2.4% — -$614.1K -$61.3M
FY 2023 $8.7M $7.9M — — -$17.0M -$69.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HIND // BETA —
BOLT // BETA —